Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk (NYSE: NVO )’s Wegovy across five ...

Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and ... which makes the anti-obesity injection Zepbound. Novo Nordisk's shares tumbled last ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.

The drugs help severely obese children to lose weight on top of the diet and lifestyle plan they are already following.

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...